Contineum Therapeutics, Inc.
CTNMHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeContineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in. Valued at $312.6M, CTNM is a small-cap name in its sector. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Market Cap
$312.6M
Beta
0.86
P/E (TTM)
—
P/E (Fwd)
-4.31
EPS (TTM)
$-1.71
EPS (Fwd)
$-1.93
ROE
-28.0%
ROA
-19.1%
Cash
$236.6M
Total Debt
$6.6M
Free CF
-$35.1M
52W Change
-24.8%
Annual Financials
Cash vs Debt
Where CTNM stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, CTNM finished 48.21% below its 150-day moving average ($13.67) and 48.09% below its 200-day moving average ($13.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CTNM overbought or oversold?
At the October 19, 2026 close, CTNM's RSI(14) was 24.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $236.6M in cash comfortably exceeding the $6.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$35.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -28.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CTNM.